SCHEMBL26315

SCHEMBL26315

CCC(OC(C)=O)N(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.40
KCNH2 Q12809 1/20 0.37
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM1 P11229 1/20 0.35
TBXA2R P21731 1/20 0.35
LMNA P02545 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HSD17B10 Q99714 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
GALR3 O60755 1/20 0.34
MAPT P10636 1/20 0.34
BLM P54132 1/20 0.34
TDP1 Q9NUW8 1/20 0.33
ALOX15 P16050 1/20 0.32
MEN1 O00255 1/20 0.31
CYP1A2 P05177 1/20 0.31
HRH1 P35367 1/20 0.31
KMT2A Q03164 1/20 0.31
USP2 O75604 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL7710344 0.98 TSHR (0.39) TSHRKCNH2CHRM2CHRM4CHRM1
SCHEMBL9818650 0.87 TDP1 (0.43) TSHRKCNH2TDP1
SCHEMBL6517414 0.82 TSHR (0.37) TSHRKCNH2CHRM2CHRM4CHRM1
SCHEMBL25362541 0.81 KCNH2 (0.31) TSHRKCNH2USP2
SCHEMBL611932 0.79 TSHR (0.39) TSHRKCNH2CHRM2CHRM4CHRM1
SCHEMBL20001689 0.79 CHRNB2 (0.39) TSHRCHRM2CHRM4CHRM1LMNA
SCHEMBL11549731 0.79 CHRNB2 (0.39) CHRM2CHRM4CHRM1
SCHEMBL7718350 0.79 ALDH1A1 (0.32) TSHRALDH1A1
SCHEMBL28669002 0.79 ALDH1A1 (0.39) TSHRLMNAALDH1A1
SCHEMBL137792 0.79 TSHR (0.39) TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3368089-A1 NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES TRANSLATE BIO MA, INC. (US) 2018-09-05 EP claimed
WO-2017075038-A1 NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES RANA THERAPEUTICS, INC. (US) 2017-05-04 WO claimed
EP-4735415-A1 CALIXARENE COMPOUNDS, THEIR SYNTHESIS AND USE IN PHARMACEUTICAL COMPOSITIONS Phoenix Biosciences SA (BE) 2026-05-06 EP disclosed
WO-2025229369-A1 SYNTHETIC NUCLEIC ACID MOLECULES AND USE THEREOF 삼성바이오로직스 주식회사 2025-11-06 WO disclosed
US-12297432-B2 Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity TAKEDA PHARMACEUTICALS U.S.A., INC. (US) 2025-05-13 US disclosed
EP-4531902-A1 NUCLEIC ACID BASED VACCINE ENCODING AN ESCHERICHIA COLI FIMH ANTIGENIC POLYPEPTIDE CureVac SE (DE) 2025-04-09 EP disclosed
WO-2025019903-A1 RNA VACCINES FOR USE IN ANIMAL HEALTH Denteric Pty Ltd (AU) 2025-01-30 WO disclosed
WO-2024223953-A1 CALIXARENE COMPOUNDS, THEIR SYNTHESIS AND USE IN PHARMACEUTICAL COMPOSITIONS QUANTOOM BIOSCIENCES S.A. (BE) 2024-10-31 WO disclosed
EP-4444885-A2 IRNA COMPOSITIONS AND METHODS FOR SILENCING MYLIP Alnylam Pharmaceuticals, Inc. (US) 2024-10-16 EP disclosed
EP-4402261-A1 IRNA COMPOSITIONS AND METHODS FOR SILENCING ANGPTL4 Alnylam Pharmaceuticals, Inc. (US) 2024-07-24 EP disclosed
WO-2024125597-A1 COMPOSITIONS AND METHODS FOR INFECTIOUS DISEASES PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) 2024-06-20 WO disclosed
WO-2012027713-A2 COMPOSITIONS AND METHODS FOR INHIBITION OF SNCA ALNYLAM PHARMACEUTICALS, INC. (US) 2012-03-01 WO disclosed
US-20120041134-A1 CONJUGATED DIENE-BASED POLYMER, CONJUGATED DIENE-BASED POLYMER COMPOSITION, AND PROCESS FOR PRODUCING CONJUGATED DIENE-BASED POLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-02-16 US disclosed
US-20110237737-A1 CONJUGATED DIENE POLYMER RUBBER, AND CONJUGATED DIENE POLYMER RUBBER COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-09-29 US disclosed
WO-2011108955-A1 MULTI -TARGETING SYSTEM COMPRISING A NANOCARRIER, NUCLEIC ACID(S) AND NON-NUCLEIC ACID BASED DRUG(S) UNIVERSIDADE DE COIMBRA (PT) 2011-09-09 WO disclosed
EP-2344639-A2 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN Alnylam Pharmaceuticals, Inc. (US) 2011-07-20 EP disclosed
EP-2250266-A2 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD45 GENE Alnylam Pharmaceuticals Inc. (US) 2010-11-17 EP disclosed
WO-2010048228-A2 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN ALNYLAM PHARMACEUTICALS, INC. (US) 2010-04-29 WO disclosed
WO-2009137128-A2 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD45 GENE ALNYLAM PHARMACEUTICALS, INC. (US) 2009-11-12 WO disclosed
US-6201093-B1 MERCAPTO-FUNCTIONAL POLYSILOXANES MODIFIED WITH ETHENICALLY UNSATURATED COMPOUNDS CONTAINING AMINO GROUPS; USE AS TEXTILE FINISHING AIDS, SURFACTANTS AND EMULSIFIERS HUELS AKTIENGESELLSCHAFT (DE) 2001-03-13 US disclosed